Head to Head Review: AxoGen (NASDAQ:AXGN) vs. GE HealthCare Technologies (NASDAQ:GEHC)

GE HealthCare Technologies (NASDAQ:GEHC) and AxoGen (NASDAQ:AXGN) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, dividends, valuation, earnings, profitability, risk and institutional ownership.

Valuation & Earnings

This table compares GE HealthCare Technologies and AxoGen”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GE HealthCare Technologies	$20.62 billion	1.40	$2.08 billion	$4.36	14.67
AxoGen	$225.21 million	9.53	-$15.70 million	($0.68)	-58.71

GE HealthCare Technologies has higher revenue and earnings than AxoGen. AxoGen is trading at a lower price-to-earnings ratio than GE HealthCare Technologies, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

82.1% of GE HealthCare Technologies shares are owned by institutional investors. Comparatively, 80.3% of AxoGen shares are owned by institutional investors. 0.4% of GE HealthCare Technologies shares are owned by insiders. Comparatively, 2.4% of AxoGen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares GE HealthCare Technologies and AxoGen’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
GE HealthCare Technologies	9.33%	20.12%	5.74%
AxoGen	-13.36%	-8.90%	-6.47%

Analyst Ratings

This is a summary of recent recommendations for GE HealthCare Technologies and AxoGen, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GE HealthCare Technologies	0	11	11	0	2.50
AxoGen	1	2	10	0	2.69

GE HealthCare Technologies presently has a consensus target price of $78.39, suggesting a potential upside of 22.52%. AxoGen has a consensus target price of $51.33, suggesting a potential upside of 28.59%. Given AxoGen’s stronger consensus rating and higher probable upside, analysts plainly believe AxoGen is more favorable than GE HealthCare Technologies.

Risk and Volatility

GE HealthCare Technologies has a beta of 0.7, indicating that its share price is 30% less volatile than the S&P 500. Comparatively, AxoGen has a beta of 1.16, indicating that its share price is 16% more volatile than the S&P 500.

Summary

GE HealthCare Technologies beats AxoGen on 9 of the 14 factors compared between the two stocks.

About GE HealthCare Technologies

GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, image-guided therapy, X-ray systems, and women’s health products. The Ultrasound segment provides medical devices and solutions for screening, diagnosis, treatment, and monitoring of certain diseases in clinical areas, such as radiology and primary care, women’s health, cardiovascular, and point of care and handheld ultrasound solutions, as well as surgical visualization and guidance products. The Patient Care Solutions segment provides medical devices, consumables, services, and digital solutions. Its portfolio includes patient monitoring solutions, anesthesia delivery and respiratory care products, electrocardiogram solutions, maternal infant care products, and consumables and services. The Pharmaceutical Diagnostics supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, positron emission tomography, and ultrasound to the radiology and nuclear medicine industry. The segment also provides contrast media pharmaceuticals that are administered to a patient prior to certain diagnostic scans to increase the visibility of tissues or structures during imaging exams; and molecular imaging agents or radiopharmaceuticals, which are molecular tracers labeled with radioisotopes. It has an AI collaboration with Mass General Brigham. The company was formerly known as GE Healthcare Holding LLC and changed its name to GE HealthCare Technologies Inc. in December 2022. The company was incorporated in 2022 and is headquartered in Chicago, Illinois.

About AxoGen

AxoGen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen, Inc. is headquartered in Alachua, Florida.